Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis Dong Hwan Kim

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
Haematologica|December 3, 2019
Are we ready to use precision medicine in chronic myeloid leukemia practice?Dennis Dong Hwan Kim
Blood|January 15, 2026
A small step yet one giant leap for cGVHD biomarkersIgor Novitzky-Basso, Dennis Dong Hwan Kim
Haematologica|June 19, 2025
Olverembatinib in chronic myeloid leukemia: is less actually better?Maria Agustina Perusini, Dennis Dong Hwan Kim
Current Opinion in Hematology|October 4, 2018
Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndromeRoman M Shapiro, Dennis Dong Hwan Kim
Future Oncology (London, England)|January 9, 2025
Asciminib versus bosutinib following 2 or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL studyNatasha Szuber, Lisa Machado, Dennis Dong Hwan Kim
Leukemia & Lymphoma|August 11, 2021
Early prediction of stable MR<sup>4.5</sup> by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinibAisling Nee, Jeffrey H Lipton, Dennis Dong Hwan Kim
British Journal of Haematology|October 3, 2023
Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directionsElizabeth Herrity, Mariana Pinto Pereira, Dennis Dong Hwan Kim
Drugs & Aging|March 11, 2016
Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic PhaseUday Deotare, Dennis Dong Hwan Kim, Jeffrey H Lipton
International Journal of Hematology|March 27, 2021
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemiaHyewon Lee, Igor Novitzky Basso, Dennis Dong Hwan Kim
JAMA|July 11, 2023
DNA Sequencing in Adults With Acute Myeloid Leukemia to Detect Residual Disease Prior to Hematopoietic Cell TransplantNiranjan Shiwaji Khaire, Dennis Dong Hwan Kim, Arjun D Law
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
Haematologica|December 3, 2019
Are we ready to use precision medicine in chronic myeloid leukemia practice?Dennis Dong Hwan Kim
Blood|January 15, 2026
A small step yet one giant leap for cGVHD biomarkersIgor Novitzky-Basso, Dennis Dong Hwan Kim
Haematologica|June 19, 2025
Olverembatinib in chronic myeloid leukemia: is less actually better?Maria Agustina Perusini, Dennis Dong Hwan Kim
Current Opinion in Hematology|October 4, 2018
Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndromeRoman M Shapiro, Dennis Dong Hwan Kim
Future Oncology (London, England)|January 9, 2025
Asciminib versus bosutinib following 2 or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL studyNatasha Szuber, Lisa Machado, Dennis Dong Hwan Kim
Leukemia & Lymphoma|August 11, 2021
Early prediction of stable MR<sup>4.5</sup> by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinibAisling Nee, Jeffrey H Lipton, Dennis Dong Hwan Kim
British Journal of Haematology|October 3, 2023
Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directionsElizabeth Herrity, Mariana Pinto Pereira, Dennis Dong Hwan Kim
Drugs & Aging|March 11, 2016
Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic PhaseUday Deotare, Dennis Dong Hwan Kim, Jeffrey H Lipton
International Journal of Hematology|March 27, 2021
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemiaHyewon Lee, Igor Novitzky Basso, Dennis Dong Hwan Kim
JAMA|July 11, 2023
DNA Sequencing in Adults With Acute Myeloid Leukemia to Detect Residual Disease Prior to Hematopoietic Cell TransplantNiranjan Shiwaji Khaire, Dennis Dong Hwan Kim, Arjun D Law
Pageof 16